All In Biotech

NDA 207921 · Norton Waterford

Qvar Redihaler

Beclomethasone Dipropionate · Inhalation

Last checked: Nov 20, 2026Latest source record: Sep 26, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Aug 3, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

196

79 Phase 3, 14 recruiting

FAERS reports

2,861

697 serious, 37 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 30, 2025.

QVAR REDIHALER is indicated in the maintenance treatment of asthma as prophylactic therapy in adults and pediatric patients 4 years of age and older. Limitations of Use: QVAR REDIHALER is not indicated for the relief of acute bronchospasm. QVAR REDIHALER is a corticosteroid indicated for maintenance treatment of asthma as prophylactic therapy in adults and pediatric patients 4 years of age and older. ( 1 ) Limitations of Use : Not indicated for the relief of acute bronchospasm. ( 1 )

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 3, 2017 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
2 products under this application
  • QVAR REDIHALER · BECLOMETHASONE DIPROPIONATE 0.04MG/INH · AEROSOL, METERED, INHALATION · Prescription
  • QVAR REDIHALER · BECLOMETHASONE DIPROPIONATE 0.08MG/INH · AEROSOL, METERED, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Beclomethasone Dipropionate" as an intervention, any sponsor and status, largest first.

All 196 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective393
  • asthma346
  • dyspnoea324
  • cough265
  • device malfunction255
  • device delivery system issue194
  • device issue178
  • product use in unapproved indication126
  • headache125
  • wrong technique in product usage process112
  • product dose omission issue108
  • fatigue99

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20131
20161
20171
2018355
2019475
2020349
2021308
2022349
2023282
2024331
2025235
2026174

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Qvar Redihaler (Beclomethasone Dipropionate)

2024 spending

$72.5M

Beneficiaries

83,367

222,782 claims

Per beneficiary

$870

$23.77 per unit

View as table
YearSpending
2020$59,157,028
2021$52,807,432
2022$48,407,638
2023$48,874,607
2024$72,512,833

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 906 on PubMed

Sponsor: Norton Waterford

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.